Company intelligence / Profile preview

OCEAN Dx

Ownership: Private
Development stage: Preclinical

Overview

OCEAN Dx has developed a patented multiplexing molecular diagnostic test capable of detecting and identifying 99% of sepsis-causing pathogens from whole blood samples in less than 5 hours. The company is currently conducting a clinical study with Bordeaux University Hospital to evaluate the performance of its rapid sepsis diagnostic prototype on 110 patients. Early results aim to demonstrate improved speed and accuracy over traditional blood cultures.

Therapeutic areas: Infectious Diseases
Modalities: DeviceMolecular diagnostics kit
Industry: Molecular Diagnostics

Partnerships

Bordeaux University Hospital / Haut-Lévêque Hospital for clinical studies

Beyond the preview

Go deeper on OCEAN Dx.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on OCEAN Dx.

Explore the full profile